Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Govt announces Rs 11,336 crore capital infusion in 5 banks

32m moneycontrol
The government has announced an infusion of Rs 11,336 crore in five public sector banks as part of its Indradhanush scheme, which was unveiled in 2015. This is the last tranche of infusion under the scheme.
532179 532388 IOB PNJZY 532461 CRPKY 532480 532418 ALBK PNB CORPBANK ANDHRABANK

0
PSU bank stocks surge up to 11% on capital infusion reports

1h thehindubusinessline
PSU bank stocks today surged up to 11 per cent amid reports that the finance ministry is likely to infuse about Rs 10,000 crore within a few days in some state-owned lenders to help them meet regulatory capital requirement.
INDIANB IOB ALBK 532418 532814 CNRYY 532179 532388 PNJZY 532121 532483 532461 CRPKY 532480 PNB CORPBANK CANBK DENABANK ANDHRABANK

0
Sensex recovers 196 pts on sharp fall in crude prices

2h freepressjournal.in
Mumbai: The Sensex today rebounded by over 196 points to close at 36,519.96 as oil, metal and PSU stocks rallied after a sharp drop in global crude oil prices. Sentiment got a boost after crude oil prices in global markets dropped by over 4 per cent yesterday owing to oversupply fears, helping the rupee to strengthen against the dollar, brokers said.
532179 CRPKY CORPBANK

0
News In Numbers: LIC holds more than 10% stake in 6 public sector banks

7h livemint
What is it? China’s growth in second quarter of 2018, compared to same period last year.
532179 500116 CRPKY IDBI CORPBANK

0
Corporation Bank - Updates

2018-07-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532179 CRPKY CORPBANK

0
PSU banks plan to raise over Rs 50k crore equity capital in FY19

2018-07-08 moneycontrol
Public sector banks are planning to tap the markets to raise more than Rs 50,000 crore this fiscal to shore up their capital base for business growth and meeting regulatory global risk norms.
ALBK 532505 CNRYY 532179 SYNDIBANK 532276 532121 532483 CRPKY 532480 CORPBANK UCOBANK CANBK DENABANK

0
Corporation Bank - Others

2018-07-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532179 CRPKY CORPBANK

5
Bank Boards Bureau recommends 15 names for the post of MD in PSU banks

2018-06-30 livemint
Mumbai: The Bank Boards Bureau has recommended the names of 15 officials for the posts of managing director and chief executive officers in several public sector banks.
INDIANB UBNC 500116 UDBKL IDBI ALBK UBLS 532814 CNRYY 532179 SYNDIBANK 532276 532483 CRPKY UBLA 532480 CORPBANK CANBK SBAZ

0
Corporation Bank - Shareholders meeting

2018-06-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532179 CRPKY CORPBANK

0
Corporation Bank - Shareholders meeting

2018-06-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532179 CRPKY CORPBANK

0
Corporation Bank - Shareholders meeting

2018-06-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532179 CRPKY CORPBANK

3
Post IDBI Bank deal, LIC may have to pare stakes in other banks

2018-06-28 moneycontrol
If Life Insurance Corporation of India's IDBI Bank buy goes through, it could be asked to cap its equity stake in several banks — public sector and private — at 15 percent.
532179 500116 PNJZY 532461 CRPKY IDBI PNB CORPBANK SBAZ 532401 VIJAYABANK

3
NPA-hit PSBs aim to get out of RBI watchlist by ’20

2018-06-27 freepressjournal.in
New Delhi : Eleven public sector banks that are under the RBI’s watchlist for mounting bad loans on Tuesday expressed confidence before a parliamentary committee that they would emerge out of the central bank’s Prompt Corrective Action (PCA) framework by 2020, sources said.
IOB 500116 UDBKL IDBI ALBK UBLS 532505 532179 532388 532121 CRPKY UBLA 532480 CORPBANK UCOBANK DENABANK

3
11 heads to appear before parliamentary panel tomorrow

2018-06-25 freepressjournal.in
New Delhi: Heads of 11 state-owned banks will apprise a parliamentary committee of the problems of mounting bad loans and increasing fraud cases on Tuesday, sources said.
IOB 500116 UDBKL IDBI ALBK UBLS 532505 532179 532388 532121 CRPKY UBLA 532480 CORPBANK UCOBANK DENABANK

10
Heads of 11-PSBs to appear before par panel on Tuesday

2018-06-24 moneycontrol
Heads of 11-state-owned banks will apprise a parliamentary committee about the problems of mounting bad loans and increasing fraud cases on Tuesday, sources said.
FISI IOB 500116 UDBKL IDBI ALBK UBLS 532505 FIISO FIISP 532179 532388 532121 CRPKY UBLA 532480 CORPBANK UCOBANK DENABANK

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...